Core Insights - Tianjin Tasly Pharmaceutical announced a revenue of 2.022 billion yuan for Q3 2025, representing a year-on-year decline of 3.27% [1] - The net profit attributable to shareholders for Q3 2025 was 210 million yuan, showing a year-on-year increase of 16.56% [1] - For the first three quarters of 2025, the company reported a total revenue of 6.311 billion yuan, down 2.35% year-on-year [1] - The net profit attributable to shareholders for the first three quarters of 2025 reached 984 million yuan, reflecting a year-on-year growth of 16.88% [1]

Core Insights - The company Tianjin Tasly Pharmaceutical Co., Ltd. reported a third-quarter revenue of 2.022 billion yuan, representing a year-on-year decline of 3.27% [1] - The net profit attributable to shareholders of the listed company was 210 million yuan, showing a year-on-year increase of 16.56% [1] - The net profit attributable to shareholders after deducting non-recurring gains and losses was 189 million yuan, reflecting a year-on-year decrease of 23.64% [1] - The basic earnings per share were 0.14 yuan [1]

Core Insights - Despite the overall decline in the national pharmaceutical manufacturing industry, the company Tianjin Tasly Pharmaceutical is experiencing growth, with a focus on innovative traditional Chinese medicine and biopharmaceuticals as dual engines for research and development [1][2] - The company has made significant progress in its innovative drug pipeline, with 31 innovative drugs currently under research, including new indications for its flagship drug and several other products entering clinical trials [2][3] Industry Performance - As of August, the national pharmaceutical manufacturing industry's cumulative revenue was 15,833.10 billion yuan, a year-on-year decrease of 2.0%, while the total profit dropped by 3.9% to 2,129.50 billion yuan [1] Company Developments - In the third quarter, the company announced multiple achievements in its innovative drug research, including the approval of a new indication for its major biopharmaceutical product for acute ischemic stroke and the launch of a traditional Chinese medicine product [2] - The company is strategically focusing on three major disease areas: cardiovascular and metabolic diseases, neurological/psychiatric disorders, and digestive diseases, while avoiding excessive competition in saturated markets [3] - The company has received clinical approvals for three advanced treatment products, including the world's first mesenchymal stem cell injection approved for IND in the U.S. [3] - The company is advancing its PD-L1/VEGF dual antibody product through clinical trials, which aims to enhance anti-tumor activity by blocking multiple pathways [3]

Group 1 - Company Tianshili reported Q3 2023 revenue of approximately 6.311 billion yuan, a year-on-year decrease of 2.35% [1] - The net profit attributable to shareholders was approximately 984 million yuan, reflecting a year-on-year increase of 16.88% [1] - Basic earnings per share were 0.66 yuan, an increase of 17.86% year-on-year [1] Group 2 - As of the report, Tianshili's market capitalization stands at 23.5 billion yuan [2] - The Chinese innovative drug sector has seen overseas licensing sales reach 80 billion USD this year [2] - There is a contrast in the biopharmaceutical secondary market's activity compared to the primary market, which is experiencing a fundraising slowdown [2]

Core Viewpoint - Tianjin Tasly Pharmaceutical Group Co., Ltd. held its 15th meeting of the 9th Board of Directors on October 23, 2025, to review the Q3 2025 report and other documents [1] Company Summary - For the fiscal year 2024, the revenue composition of Tasly is as follows: Traditional Chinese Medicine accounts for 70.89%, Chemical Preparations 15.38%, Pharmaceutical Commerce 10.53%, Biopharmaceuticals 2.25%, and Chemical Raw Materials 0.61% [1] - As of the report date, Tasly's market capitalization stands at 23.5 billion yuan [1] Industry Summary - In 2023, Chinese innovative drugs have generated overseas licensing sales of 80 billion USD [1] - The secondary market for biomedicine is experiencing a surge, while the primary market is facing challenges in fundraising [1]

10月24日晚间，天士力（600535）发布三季报称，公司前三季实现医药工业收入57.09亿元，保持稳 健；归母净利润达到9.84亿元，同比增长16.88%，逆转行业下降趋势实现增长。公司重磅产品普佑克获 准拓展脑梗适应症，为公司未来业绩提供增量贡献。 主营业务保持增长，新适应症获批支持持续增长 在全国医药制造业表现不佳的背景下，天士力的逆势增长殊为不易。国家统计局数据显示，截止8月全 国医药制造业营业收入累计值为15833.10亿元，同比下降2.0%；同期医药制造业利润总额累计值 2129.50亿元，同比下降3.9%。 同时，公司重磅生物创新药普佑克此前获得国家药监局批准新增适应症，用于急性缺血性脑卒中(AIS) 的溶栓治疗。相较于其他溶栓药物，普佑克作为特异性溶栓药，溶栓机制独特，全身系统性出血风险 小，安全性高，溶栓后再栓率低，生产工艺先进。券商研报指出，普佑克脑梗适应症上市后，未来有望 成长为过十亿的品种。中信建投（601066）证券近期研报称，随着AIS发病率及溶栓治疗渗透率的持续 提升，叠加三九赋能销售渠道协同，普佑克销售潜力有望持续释放，预测销售峰值超过10亿元。信达证 券（601059）研报也 ...

Core Insights - China Resources Pharmaceutical (03320.HK) reported that Tianjin Tasly Pharmaceutical achieved total revenue of RMB 6.311 billion for the nine months ending September 30, 2025, a year-on-year decrease of 2.35% [1] - The net profit for Tianjin Tasly Pharmaceutical was RMB 999 million, reflecting a year-on-year increase of 19.85% [1] - As of the end of the reporting period, the cash and cash equivalents balance stood at RMB 1.183 billion [1] Group 1 - Tianjin Tasly Pharmaceutical's total revenue decreased by 2.35% year-on-year to RMB 6.311 billion [1] - The net profit increased by 19.85% year-on-year to RMB 999 million [1] - The cash and cash equivalents at the end of the period were RMB 1.183 billion [1] Group 2 - China Resources Pharmaceutical holds approximately 28% equity in Tianjin Tasly Pharmaceutical through its non-wholly owned subsidiary, China Resources Sanjiu Medical & Pharmaceutical Co., Ltd. [1] - The shares of Tianjin Tasly Pharmaceutical are listed on the Shanghai Stock Exchange [1]

Core Viewpoint - China Resources Pharmaceutical (03320) reported Tianjin Tasly Pharmaceutical (600535) unaudited financial performance for the nine months ending September 30, 2025, showing a decline in total revenue but an increase in net profit [1] Financial Performance Summary - Total revenue for the period was approximately 6.311 billion yuan, representing a year-on-year decrease of 2.35% [1] - Net profit for the same period was approximately 992.5 million yuan, reflecting a year-on-year increase of 19.85% [1]

智通财经APP讯，华润医药(03320)公布天士力医药截至2025年9月30日止九个月的未经审核财务业绩， 营业总收入约63.11亿元，同比减少2.35%;净利润约9.925亿元，同比增长19.85%。 ...

证券代码：600535 证券简称：天士力 编号：临 2025-070 号 一、报告期内分行业经营数据 二、报告期内分治疗领域经营数据 单位：元 币种：人民币 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连带责任。 根据上海证券交易所《上海证券交易所上市公司自律监管指引第 3 号—行业信 息披露》及《关于做好主板上市公司 2025 年三季度报告披露工作的重要提醒》的 要求，现将公司 2025 年前三季度主要经营数据披露如下： | 分治疗领域 | 营业收入 | 营业成本 | 毛利率 （%） | 营业收入比 上年增减 | 营业成本比 上年增减 | 毛利率比 上年增减 | | --- | --- | --- | --- | --- | --- | --- | | | | | | （%） | （%） | （%） | | 心血管及代谢 | 3,186,385,371.50 | 714,635,379.65 | 77.57 | 1.16 | 6.43 | -1.11 | | 神经/精神 | 1,085,227,997.38 | 548,643 ...